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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To determine whether antibiotic therapy is safe and eGective for the induction and maintenance of remission in ulcerative colitis (UC).
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B A C K G R O U N D
Description of the condition
Ulcerative colitis (UC) is a chronic inflammation of the colon,
characterised by periods of relapse and remission (Ordas 2012).
Symptoms can include persistent diarrhoea, which may oen be
bloody, problems with defecation, abdominal pain, rectal pain and
bleeding, weight loss and fatigue. It starts in the rectum and extends
throughout the colon. UC and Crohn’s disease (CD) are the two
most common inflammatory bowel diseases (IBDs). UC tends to be
more common than CD, with an estimated prevalence of 90 to 505
cases per 100,000 people in North America and Northern Europe
(Conrad 2014). Whilst prevalence of UC has been historically higher
in Western countries, its incidence in industrialised parts of Asia and
Latin America is on the rise. The cause of UC is not known but is
believed to be associated with certain genetic and environmental
factors. The risk of developing UC is higher in Ashkenazi Jews,
people with a family history of the disease and those who live in
Western countries (da Silva 2014).
Description of the intervention
It has been proposed that there is a link between increased
intestinal bacterial concentrations and chronic inflammation
(Swidsinksi 2002; Vrakas 2017). Studies have suggested bacterial
pathogens, such as Escherichia coli, Bacteroides spp, and
Mycobacterium avium, are linked to the pathogenesis of UC.
Antibiotics may influence the course of UC by decreasing the
number of bacteria in the gut and altering the composition of
the microbiome. Specific antibiotics that have been used for
this purpose include ciprofloxacin, metronidazole, rifaximin, anti-
tuberculous regimens and antibiotic combinations among others
(Nitzan 2016). Oral administration of the antibiotics is the most
common route. For induction of remission, antibiotics can be taken
from a few days up to a month and for maintenance of remission
from a few months to a year.
How the intervention might work
Several antibiotics have been evaluated for the treatment of
UC. Reduction of the bacterial load in the intestinal mucosa
might reduce the pathological immune response in the intestinal
mucosa. Furthermore, antibiotics also act to limit bacterial
translocation and reduce the concentration of adherent bacteria
to the lumen and mucosa (Scribano 2013). In patients with high
levels of Escherichia coli in their microbiome, treatment with
mesalamine showed a decrease in intestinal inflammation; this
further suggests the crucial role the gut microbiome may have
in IBD pathophysiology and the potential for treatment with
antimicrobial agents (Kostic 2014). There is a possibility that
alteration of the mucosal flora may have a therapeutic role in UC by
inhibiting the stimulus for pathogenic immune responses (Ott 2004;
Swidsinksi 2002).
Why it is important to do this review
Given the possible role of the bacterial load in the pathogenesis
of UC, it is reasonable to postulate that antibiotic therapy might
be eGective for either induction or maintenance of remission in
UC. However, several potential problems exist with this approach.
First, use of broad-spectrum antibiotics is a very generalised
strategy that may aggravate the aforementioned dysbiosis. Second,
the resident flora are determined by both genetic and dietary
factors that may be diGicult or impossible to modify on a
chronic basis; therefore, treatment (if eGective) might have to be
continued indefinitely. Finally, broad-spectrum antibiotic therapy
is associated with important adverse eGects, notably an increased
risk of C. di (Clostridioides diicile, previously known as Clostridium
diicile) infection. For these reasons, evidence from high-quality
randomised controlled trials (RCTs) is necessary before antibiotics
are accepted as eGective and safe for the treatment of UC.
No current recommendations exist regarding the antibiotic of
choice, dose, or duration for treatment of UC. Despite limited
supporting evidence, the most recent guidelines published by the
World Gastroenterology Organisation support the use of antibiotics
in perianal disease, fistulising disease, and bacterial overgrowth
secondary to stricturing disease (Bernstein 2016). A previous meta-
analysis on this topic (Rahimi 2007) suggested that adjunctive
antibacterial therapy is eGective for induction of clinical remission
in UC. However, recently published international guidelines do
not recommend the routine use of antibiotics for induction and
maintenance of remission in the management of UC, since trials
of oral or intravenous antibiotics have not demonstrated any
consistent benefit compared to conventional therapies, and a
possible role is only suggested in case of infection or prior to
surgery (Feuerstein 2020; Harbord 2017; Rubin 2019; Singh 2020).
This Cochrane Review aims to examine the current evidence from
RCTs that investigate the role of antibiotics in the induction and
maintenance of remission in UC.
O B J E C T I V E S
To determine whether antibiotic therapy is safe and eGective for the
induction and maintenance of remission in ulcerative colitis (UC).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only stydies with a randomised controlled trial (RCT) study design
will be considered for inclusion, including cluster RCTs.
Cross-over RCTs will only be included if results are presented
seperately for each stage of the trial, or if we can obtain them aer
contact with the authors.
Types of participants
Participants of any age and with any disease stage or extent will be
considered for inclusion.
Participants with active or quiescent UC (as defined by the original
studies) will be considered for inclusion.
Types of interventions
All types/classes of antibiotics will be considered, with any route
of delivery (i.e. oral, intravenous). Trials that compare antibiotic
therapy to a placebo or an active comparator will be considered
for inclusion. Antibiotics used as adjunctive therapies or as
monotherapy will be considered for inclusion.
Studies on induction of remission must have a minimum duration
of at least two weeks to be considered for inclusion. Studies on
maintenance of remission must have a minimum duration of at
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least three months to be considered for inclusion. We will exclude
studies in which placebo or comparator groups have had recent
antibiotic exposure (i.e. within the past six months).
Types of outcome measures
Primary outcomes
For studies on induction of remission, the primary outcome
measure will be the proportion of participants who failed to achieve
remission, as defined by the original studies.
For studies on maintenance of remission, the primary outcome
measure will be the proportion of participants who relapsed, as
defined by the included studies.
Secondary outcomes
E8icacy outcomes
1. The proportion of participants who failed to achieve clinical
response (as defined by the original studies)
2. The proportion of participants who failed to achieve endoscopic
remission (as defined by the original studies)
3. The proportion of participants who failed to achieve histological
remission (as defined by the original studies)
4. The proportion of participants who had an endoscopic relapse
(as defined by the original studies)
5. Health-related quality of life (as measured by a validated quality-
of-life instrument)
Safety outcomes
1. The proportion of participants with any adverse event (AE)
2. The proportion of participants with serious adverse events
(SAEs), as defined by the original studies
3. The proportion of participants who withdrew from the study due
to adverse events
Search methods for identification of studies
Electronic searches
We will search the following databases for relevant studies.
1. Cochrane Central Register of Controlled Trials (CENTRAL) and
Cochrane Database of Systematic Reviews (CDSR) (via Ovid)
(Appendix 1)
2. MEDLINE (Ovid, 1946 to present) (Appendix 2)
3. Embase (Ovid, 1974 to present) (Appendix 3)
4. The Cochrane Gut Group Specialized Register (previously The
Cochrane IBD Group Specialized Register)
5. ClinicalTrials.gov
Searching other resources
We will search the references listed in relevant studies and
review articles for additional citations not identified in the search.
Furthermore, we will search the conference proceedings from
major meetings (Digestive Disease Week, the European Crohn's
and Colitis Organisation congress, and the United European
Gastroenterology Week conference) from the last five years, for
studies published in abstract form only.
Data collection and analysis
Selection of studies
Two review authors will independently screen the search results
for eligible studies based on the inclusion criteria as listed. Any
disagreements will be brought to a third author and will be
discussed until a consensus is reached.
Data extraction and management
Data will be extracted from included studies by two review authors,
independently. Any disagreements over extracted data will be first
discussed and then brought to a third review author for resolution
if deemed necessary.
Assessment of risk of bias in included studies
Two review authors will independently assess all studies meeting
the inclusion criteria for their risk of bias using criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). The following domains will be assessed.
• Sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants and personnel (performance bias)
• Blinding of outcome assessment (detection bias)
• Incomplete outcome data (attrition bias)
• Selective reporting (reporting bias)
• Other bias (such as imbalance in participants' baseline
characteristics)
We will judge the studies to be at low, high or unclear risk of bias
for each domain assessed, based on the guidance in Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will classify overall risk of bias in the trials as being low if all the
bias domains are classified as being at low risk of bias; and we will
classify overall risk of bias as high if one or more of the bias domains
described in the above paragraphs are classified as being at unclear
or high risk of bias.
Aer data extraction, the two review authors will compare the
extracted data and discuss and resolve discrepancies before the
data are transferred into the 'Characteristics of included studies'
table. For cluster-RCTs, we intend to judge risk of bias as prescribed
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011)
Measures of treatment e8ect
We will use Review Manager 5 to analyse the data on an intention-
to-treat (ITT) basis. We will use risk ratios (RRs) for dichotomous
outcomes, with 95% confidence intervals (CIs). For continuous
outcomes, we will calculate the mean diGerence (MD) if all studies
reported their outcomes using the same scale, and standardised
mean diGerence (SMD) with 95% CIs if the studies used diGerent
scales to report their outcomes.
Unit of analysis issues
Cross-over trials will be included if data are available for the
first phase of the trial prior to cross-over. To deal with events
that may re-occur (e.g. adverse events), we will report on the
proportion of participants who experienced at least one event.
Separate comparisons will be performed for studies that compared
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antibiotics to placebo and for studies that compared antibiotics to
other active therapies. We will also perform separate comparisons
for each type of antibiotic. If we encounter multiple treatment
groups (e.g. for diGerent doses of antibiotics), we will divide the
placebo group across the treatment groups, or combine groups to
create a single pairwise comparison, as appropriate.
Dealing with missing data
An ITT analysis will be used for dichotomous outcomes, whereby
participants with missing treatment outcomes will be assumed to
be treatment failures. Sensitivity analyses will be performed to
assess the impact of this assumption on the eGect estimate.
Assessment of heterogeneity
We will assess heterogeneity using the Chi2 test (a P value of
0.10 will be considered statistically significant) and the I2 statistic.
We will consider an I2 statistic of 75% or greater to indicate
high heterogeneity among study data, between 75% and 50% to
indicate moderate heterogeneity, and 25% or less to indicate low
heterogeneity (Higgins 2003). Sensitivity analysis will be conducted
to explore possible explanations for heterogeneity.
Assessment of reporting biases
We will initially compare outcomes listed in the study protocols to
those reported in the published manuscripts. If we do not have
access to a study protocol, we will compare the outcomes listed
in the methods section of the published manuscript to what was
reported in the results section. If any pooled analyses include 10 or
more studies, we will investigate potential publication bias using
funnel plots (Egger 1997).
Data synthesis
Data from individual trials will be combined for meta-analysis when
the interventions, participant groups and outcomes are similar, as
deemed by author consensus. A fixed-eGect model will be used
to pool data unless significant heterogeneity exists between the
studies. A random-eGects model will be used if heterogeneity exists
(i.e. where the I2 value is 50% to 75%). We will not pool data for
meta-analysis where there is a high degree of heterogeneity (i.e. an
I2 value of 75% or greater).
Subgroup analysis and investigation of heterogeneity
If enough data are available, we plan to perform subgroup analyses
of the primary outcomes for the following factors.
1. Age of participants (children versus adults)
2. DiGerent antibiotic doses/choices
3. Duration of the intervention
4. Gender (female versus male)
5. Route of delivery (oral versus intravenous)
Sensitivity analysis
Where possible, we will undertake a sensitivity analysis for the
primary outcome of 'failure to achieve remission' for induction
studies and 'relapse' for maintenance studies, to assess whether
the findings of the review are robust to the decisions made
during the review process. In particular, we will exclude from the
analyses studies at high or unclear risk of selection bias (due
to the method of allocation concealment) and performance bias.
Where data analyses include studies with reported and estimated
standard deviations, we will exclude those with estimated standard
deviations to assess whether this aGects the findings of the review.
We will investigate whether the choice of model (fixed-eGect versus
random-eGects) may have aGected the results.
GRADE and 'Summary of findings' table
We will present the main results in a 'Summary of findings'
table. Each comparison and primary outcome will be exported to
GRADEpro GDT soware (developed by the GRADE Working Group)
for quality assessment. Data permitting, we intend to present
four 'Summary of findings' tables. Other comparisons will be
graded and presented in additional tables. Based on risk of bias,
inconsistency, imprecision, indirectness and publication bias, we
will grade the quality of the evidence for each outcome as high,
moderate, low, or very low. These ratings have been defined as
follows.
• High quality: further research is very unlikely to change our
confidence in the estimate of eGect
• Moderate quality: further research is likely to have an important
impact on our confidence in the estimate of eGect and may
change the estimate
• Low quality: further research is very likely to have an important
impact on our confidence in the estimate of eGect and is likely
to change the estimate
• Very low quality: any estimate of eGect is very uncertain
We will justify all decisions to downgrade the quality of the evidence
using footnotes, and we will make comments to aid readers'
understanding of the review where necessary. The outcomes we
plan to include in the tables are both primary outcomes and
withdrawal of participants due to adverse events.
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A P P E N D I C E S
Appendix 1. Cochrane CENTRAL and CDSR search strategy (Ovid)
1. exp ulcerative colitis/
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2. Inflammatory Bowel Diseases/
3. (colitis or proctocolitis or proctosigmoiditis or proctitis or rectosigmoiditis or rectocolitis or colorectitis or coloproctitis or UC).tw,kw.
4. inflammatory bowel disease*.tw,kw.
5. IBD.tw,kw.
6. or/1-5
7. exp Anti-Bacterial Agents/
8. exp *Anti-Infective Agents/
9. (antibiotic* or anti-biotic* or antibacterial* or anti-bacterial*).tw,kw.
10.(antimicrobial* or anti-microbial* or antiseptic* or anti-septic*).tw,kw.
11.(bactericid* or bacteriocid*).tw,kw.
12.Bacteriostatic.tw,kw.
13.(ciprofloxacin or metronidazole or levamisole or ornidazole or fusidin or rifaximin or vancomycin or fusidic acid or nitazoxanide or
teicoplanin or rifampicin or bacitracin or fidaxomicin or amoxicillin or azithromycin or cephalosporin* or cephalexin or clarithromycin




Appendix 2. MEDLINE search strategy (Ovid)
1. exp ulcerative colitis/
2. Inflammatory Bowel Diseases/
3. (colitis or proctocolitis or proctosigmoiditis or proctitis or rectosigmoiditis or rectocolitis or colorectitis or coloproctitis or UC).tw,kw.
4. inflammatory bowel disease*.tw,kw.
5. IBD.tw,kw.
6. or/1-5
7. exp Anti-Bacterial Agents/
8. exp *Anti-Infective Agents/
9. (antibiotic* or anti-biotic* or antibacterial* or anti-bacterial*).tw,kw.
10.(antimicrobial* or anti-microbial* or antiseptic* or anti-septic*).tw,kw.
11.(bactericid* or bacteriocid*).tw,kw.
12.Bacteriostatic.tw,kw.
13.(ciprofloxacin or metronidazole or levamisole or ornidazole or fusidin or rifaximin or vancomycin or fusidic acid or nitazoxanide or
teicoplanin or rifampicin or bacitracin or fidaxomicin or amoxicillin or azithromycin or cephalosporin* or cephalexin or clarithromycin












24.exp animals/ not humans.sh.
25.23 not 24
26.15 and 25
Note: Lines 16-25. RCT filter, used the “Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-
maximizing version (2008 revision); Ovid format”. We made the following minor revision: we used “random*” instead of “randomized.ab”
or “randomly.ab.” to capture word variations such as “randomised, randomization, random”.
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Appendix 3. Embase search strategy (Ovid)
1. exp ulcerative colitis/
2. inflammatory bowel disease/
3. (colitis or proctocolitis or proctosigmoiditis or proctitis or rectosigmoiditis or rectocolitis or colorectitis or coloproctitis or UC).tw,kw.
4. inflammatory bowel disease*.tw,kw.
5. IBD.tw,kw.
6. or/1-5
7. exp antibiotic agent/
8. exp *antiinfective agent/
9. (antibiotic* or anti-biotic* or antibacterial* or anti-bacterial*).tw,kw.
10.(antimicrobial* or anti-microbial* or antiseptic* or anti-septic*).tw,kw.
11.(bactericid* or bacteriocid*).tw,kw.
12.Bacteriostatic.tw,kw.
13.(ciprofloxacin or metronidazole or levamisole or ornidazole or fusidin or rifaximin or vancomycin or fusidic acid or nitazoxanide or
teicoplanin or rifampicin or bacitracin or fidaxomicin or amoxicillin or azithromycin or cephalosporin* or cephalexin or clarithromycin








20.exp animal/ not human/
21.19 not 20
22.15 and 21
Note: Lines #16-19, RCT filter, used the Hedge Best balance of sensitivity and specificity filter. https://hiru.mcmaster.ca/hiru/
HIRU_Hedges_EMBASE_Strategies.aspx
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None of these companies have had any involvement in any works completed by me and I have never had any payments for any other
activites for them, as confirmed below.
From these date onwards, I have made a personal undertaking to take no further funds from any pharmaceutical or formula company in
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This is to li the limitations such funding has on my ability to act as a first and corresponding author on reviews, in line with the Cochrane
policies on such matters and is reported in line with these policies.
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